The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued positive opinions on multiple new medicines in its December meeting. The committee recommended approval of ImmunityBio's Anktiva (nogapendekin alfa inbakicept-pmin) for BCG-unresponsive non‑muscle invasive bladder cancer and Cytokinetics’ Myqorzo (aficamten) for obstructive hypertrophic cardiomyopathy, among other recommendations. Separate CHMP notes flagged additional filings from companies including Hansoh and Cytokinetics for new indications and products.